A
Armando Orlandi
Researcher at Agostino Gemelli University Polyclinic
Publications - 105
Citations - 1427
Armando Orlandi is an academic researcher from Agostino Gemelli University Polyclinic. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 15, co-authored 77 publications receiving 875 citations. Previous affiliations of Armando Orlandi include The Catholic University of America & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Giovanni Germano,Simona Lamba,Giuseppe Rospo,Ludovic Barault,Alessandro Magrì,Federica Maione,Mariangela Russo,Giovanni Crisafulli,Alice Bartolini,Giulia Lerda,Giulia Siravegna,Benedetta Mussolin,Roberta Frapolli,Monica Montone,Federica Morano,Filippo de Braud,Nabil Amirouchene-Angelozzi,Silvia Marsoni,Maurizio D'Incalci,Armando Orlandi,Enrico Giraudo,Andrea Sartore-Bianchi,Salvatore Siena,Filippo Pietrantonio,Federica Di Nicolantonio,Alberto Bardelli +25 more
TL;DR: The inactivation of MMR increased the mutational burden and led to dynamic mutational profiles, which resulted in the persistent renewal of neoantigens in vitro and in vivo, whereas MMR-proficient cells exhibited stable mutational load and neoantigen profiles over time.
Journal ArticleDOI
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Alessandro Inno,Mariantonietta Di Salvatore,Tonia Cenci,Maurizio Martini,Armando Orlandi,Antonia Strippoli,Anna Maria Ferrara,Cinzia Bagalà,Alessandra Cassano,Luigi Maria Larocca,Carlo Barone +10 more
TL;DR: KRAS mutation significantly correlates with a worse outcome in patients treated with cetuximab, whereas no definitive inference can be drawn about the role of BRAF mutation and PTEN loss of expression and Interestingly, IGF1R overexpression seems a favorable prognostic factor in mCRC.
Journal ArticleDOI
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.
Marta Schirripa,Paola Biason,Sara Lonardi,Nicoletta Pella,Maria Simona Pino,Federica Urbano,Carlotta Antoniotti,Chiara Cremolini,Salvatore Corallo,Filippo Pietrantonio,Fabio Gelsomino,Stefano Cascinu,Armando Orlandi,Giada Munari,Umberto Malapelle,Serena Saggio,Gabriella Fontanini,Massimo Rugge,Claudia Mescoli,Stefano Lazzi,Luca Reggiani Bonetti,Giovanni Lanza,Angelo Paolo Dei Tos,Giovanna De Maglio,Maurizio Martini,Maurizio Martini,Francesca Bergamo,Vittorina Zagonel,Fotios Loupakis,Matteo Fassan +29 more
TL;DR: For the first time, different clinical and pathologic features and outcome data were reported according to the three BRAF mutation classes in mCRC.
Journal ArticleDOI
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.
M. Di Salvatore,Armando Orlandi,Cinzia Bagalà,Michela Quirino,Alessandra Cassano,Antonio Astone,Carlo Barone +6 more
TL;DR: Evaluated in vitro the anti‐tumoural and anti‐angiogenetic effect of zoledronic acid in non‐small‐cell lung cancer (NSCLC) cells.
Journal ArticleDOI
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
Fotios Loupakis,Rossana Intini,Chiara Cremolini,Armando Orlandi,Andrea Sartore-Bianchi,Filippo Pietrantonio,Nicoletta Pella,Andrea Spallanzani,Emanuela Dell'Aquila,Mario Scartozzi,Emmanuele De Luca,Lorenza Rimassa,Vincenzo Formica,Francesco Leone,Lorenzo Calvetti,Giuseppe Aprile,Lorenzo Antonuzzo,Federica Urbano,Hans Prenen,Francesca Negri,Samantha Di Donato,Pasquale Buonandi,Gianluca Tomasello,Antonio Avallone,Fable Zustovich,Roberto Moretto,Carlotta Antoniotti,Lisa Salvatore,Maria Alessandra Calegari,Salvatore Siena,Federica Morano,Elena Ongaro,Stefano Cascinu,Daniele Santini,Pina Ziranu,Marta Schirripa,Federica Buggin,Alessandra Anna Prete,Ilaria Depetris,Paola Biason,Sara Lonardi,Vittorina Zagonel,Matteo Fassan,Massimo Di Maio +43 more
TL;DR: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy and could be useful in clinical practice and may be adopted for proper adjustments in exploratory translational analyses.